LimFlow SA

Just in time for Limb Loss Awareness Month, our US pivotal trial results were published in the New England Journal of Medicine.
Six-month results showed:
•76% limb salvage
•76% of wounds were completely healed (25%) or healing (51%)
•Substantial pain reduction
•99% technical success

Recently, Dan Rose, CEO of LimFlow SA sat down with Dave Philistin, CEO of Candor to discuss the LimFlow technology and the positive impact it could have on our wellness.

Read more about LimFlow’s technology here:

Health Tech: Dan Rose On How LimFlow’s Technology Can Make An Important Impact On Our Overall… An Interview With Dave Philistin

When Dan Rose took up his role as LimFlow SA CEO, he admits he had less knowledge than he should have. Throughout his time with the company, though, he’s met numerous people who spoke of relatives affected by peripheral artery disease (PAD), chronic limb-threatening ischemia (CLTI), and major amputation.

But nobody, he said, wants to talk about it. And compared with CLTI, other so-called marquee disease states—like diabetes—simply get more attention.

“Why there has been no recognition for this disease is a mystery,” said Mary Yost, MBA, President of the Sage Group LLC. “I’ve been doing this for 20 years, and it’s like CLTI is this orphan disease that nobody’s ever heard of.”
The lack of awareness has been deadly, with PAD- and CLTI-associated mortality higher than that of even COVID-19. And like any epidemic or pandemic, there are very real socioeconomic, racial, and sex-based disparities.

“There’s not been a PAD or CLTI champion,” said Yost. With a celebrity face bringing awareness to the disease—someone with a reach like Oprah, for example—the public might one day be aware of PAD, CLTI, and their terrible impact on both life and limb.

Watch the rest of the interview with Dan Rose and Mary Yost here: https://youtu.be/-vud8aVrYVk

The Lack of Recognition for CLTI - Mary Yost, President of the Sage Group LLC When Dan Rose took up his role as LimFlow CEO, he admits he had less knowledge than he should have. Throughout his time with the company, though, he’s met nu...